Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review

Timothy J. Craig; Lynda C. Schneider; Andrew J. Macginnitie

doi:10.1111/pai.12425

Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review

Timothy J. Craig, Lynda C. Schneider, Andrew J. Macginnitie

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Presently, medications approved for children with Hereditary Angioedema (HAE) are extremely limited. This is especially the case for children under 12 years of age. For this reason we reviewed and summarized the data on treatment of children with HAE. Available data indicate that plasma derived C1-inhibitor is a safe, effective treatment option for HAE in pediatric patients, including those below 12 years of age. Other therapies are also appear safe for the under 12 year of age, but less data are available. Importantly, home-based treatment of HAE in this age group appears to be safe and effective and can improve quality of life. These findings support current HAE consensus guidelines which strongly recommend the use of plasma derived C1-inhibitor as a first-line treatment in children and encourage home and self-treatment.

Original language	English (US)
Pages (from-to)	537-544
Number of pages	8
Journal	Pediatric Allergy and Immunology
Volume	26
Issue number	6
DOIs	https://doi.org/10.1111/pai.12425
State	Published - Sep 1 2015

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health
Immunology and Allergy
Immunology

Access to Document

10.1111/pai.12425

Cite this

@article{7fe8d27cb2b74b9ab0681882ad5d4325,

title = "Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review",

abstract = "Presently, medications approved for children with Hereditary Angioedema (HAE) are extremely limited. This is especially the case for children under 12 years of age. For this reason we reviewed and summarized the data on treatment of children with HAE. Available data indicate that plasma derived C1-inhibitor is a safe, effective treatment option for HAE in pediatric patients, including those below 12 years of age. Other therapies are also appear safe for the under 12 year of age, but less data are available. Importantly, home-based treatment of HAE in this age group appears to be safe and effective and can improve quality of life. These findings support current HAE consensus guidelines which strongly recommend the use of plasma derived C1-inhibitor as a first-line treatment in children and encourage home and self-treatment.",

author = "Craig, {Timothy J.} and Schneider, {Lynda C.} and Macginnitie, {Andrew J.}",

note = "Publisher Copyright: {\textcopyright} 2015 John Wiley & Sons A/S.",

year = "2015",

month = sep,

day = "1",

doi = "10.1111/pai.12425",

language = "English (US)",

volume = "26",

pages = "537--544",

journal = "Pediatric Allergy and Immunology",

issn = "0905-6157",

publisher = "Blackwell Munksgaard",

number = "6",

}

TY - JOUR

T1 - Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients

T2 - A systematic review

AU - Craig, Timothy J.

AU - Schneider, Lynda C.

AU - Macginnitie, Andrew J.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Presently, medications approved for children with Hereditary Angioedema (HAE) are extremely limited. This is especially the case for children under 12 years of age. For this reason we reviewed and summarized the data on treatment of children with HAE. Available data indicate that plasma derived C1-inhibitor is a safe, effective treatment option for HAE in pediatric patients, including those below 12 years of age. Other therapies are also appear safe for the under 12 year of age, but less data are available. Importantly, home-based treatment of HAE in this age group appears to be safe and effective and can improve quality of life. These findings support current HAE consensus guidelines which strongly recommend the use of plasma derived C1-inhibitor as a first-line treatment in children and encourage home and self-treatment.

AB - Presently, medications approved for children with Hereditary Angioedema (HAE) are extremely limited. This is especially the case for children under 12 years of age. For this reason we reviewed and summarized the data on treatment of children with HAE. Available data indicate that plasma derived C1-inhibitor is a safe, effective treatment option for HAE in pediatric patients, including those below 12 years of age. Other therapies are also appear safe for the under 12 year of age, but less data are available. Importantly, home-based treatment of HAE in this age group appears to be safe and effective and can improve quality of life. These findings support current HAE consensus guidelines which strongly recommend the use of plasma derived C1-inhibitor as a first-line treatment in children and encourage home and self-treatment.

UR - http://www.scopus.com/inward/record.url?scp=84941216130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941216130&partnerID=8YFLogxK

U2 - 10.1111/pai.12425

DO - 10.1111/pai.12425

M3 - Article

C2 - 26111105

AN - SCOPUS:84941216130

SN - 0905-6157

VL - 26

SP - 537

EP - 544

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

IS - 6

ER -

Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this